Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1

Immunity

Volumn 6, Issue 6, 1997, Pages 773-782

  Afar, Daniel E H ^a   Limin, Han ^b   McLaughlin, Jami ^a   Wong, Stephane ^a   Dhaka, Ajay ^b   Parmar, Kalindi ^c   Rosenberg, Naomi ^c   Witte, Owen N ^a   Colicelli, John ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

ARTICLE; CANCER; CARCINOGENESIS; ENZYME LOCALIZATION; HEMATOPOIETIC CELL; NONHUMAN; PRIORITY JOURNAL; YEAST;

EID: 0342762061     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80452-5     Document Type: Article

References (63)

1. Afar, D.E.H., Goga, A., McLaughlin, J., Witte, O., and Sawyers, C.L. (1994). Differential rescue of BCR-ABL point mutants with c-MYC. Science 264, 424-426.
2. Afar, D.E.H., McLaughlin, J., Sherr, C.J., Witte, O.N., and Roussel, M.F. (1995). Signaling by ABL oncogenes through cyclin D1. Proc. Natl. Acad. Sci. USA 92, 9540-9544.
3. Cas-related protein, Sin. Genes Dev. 10, 1341-1355.
4. Alexandropoulos, K., Cheng, G., and Baltimore, D. (1995). Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc. Natl. Acad. Sci. USA 92, 3110-3114.
5. Brown, M.T., and Cooper, J.A. (1996). Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287, 121-149.
6. doc: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88, 197-204.
7. Chou, M.M., and Blenis, J. (1996). The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 85, 573-583.
8. Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
9. Elefanty, A.G., Hariharan, I.K., and Cory, S. (1990). bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9, 1069-1078.
10. Erpel, T., and Courtneidge, S.A. (1995). Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7, 176-182.
11. Feller, S.M., Ren, R., Hanafusa, H., and Baltimore, D. (1994). SH2 and SH3 domains as modular adhesives: the interaction of Crk and Abl. Trends Biochem. Sci. 19, 453-458.
12. Feng, G.S., Ouyang, Y.B., Hu, D.P., Shi, Z.Q., Gentz, R., and Ni, J. (1996). Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. J. Biol. Chem. 271, 12129-12132.
13. Franz, W.M., Berger, P., and Wang, J.Y.J. (1989). Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8, 137-147.
14. Gishizky, M.L., Johnson-White, J., and Witte, O.N. (1993). Efficient transplantation of BCR/ABL induced chronic myelogenous leukemia-like syndrome in mice. Proc. Natl. Acad. Sci. USA 90, 3755-3759.
15. Goga, A., McLaughlin, J., Afar, D.E.H., Saffran, D.C., and Witte, O.N. (1995). Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82, 981-988.
16. Han, L., and Colicelli, J. (1995). A human protein selected for interference with ras function interacts directly with ras and competes with raf1. Mol. Cell. Biol. 15, 1318-1323.
17. Han, L., Wong, D., Dhaka, A., Afar, D., White, M., Xie, W., Herschman, H., Witte, O., and Colicelli, J. (1997). Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc. Natl. Acad. Sci. USA 94, 4954-4959.
18. Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P.K., and Groffen, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature 344, 251-253.
19. Jackson, P., and Baltimore, D. (1989). N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8, 449-456.
20. Kazlauskas, A. (1994). Receptor tyrosine kinases and their targets. Curr. Opin. Genetics Dev. 4, 5-14.
21. Kelliher, M.A., McLaughlin, J., Witte, O.N., and Rosenberg, N. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
22. Kelliher, M., Knott, A., McLaughlin, J., Witte, O.N., and Rosenberg, N. (1991). Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol. Cell. Biol. 11, 4710-4716.
23. c- src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell 49, 65-73.
24. Konopka, J.B., Watanabe, S.M., and Witte, O.N. (1984). An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37, 1035-1042.
25. Kurzrock, R., Gutterman, J., and Talpaz, M. (1988). The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319, 990-998.
26. Laneuville, P. (1995). Abl tyrosine protein kinase. Semin. Immmunol. 7, 255-266.
27. Lewis, J.M., Baskaran, R., Taagepera, S., Schwartz, M.A., and Wang, J.Y.J. (1996). Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc. Natl. Acad. Sci. USA 93, 15174-15179.
28. Lugo, T., and Witte, O.N. (1989). The BCR/ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol. Cell. Biol. 9, 1263-1270.
29. Lugo, T.G., Pendergast, A., Muller, A.J., and Witte, O.N. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
30. Mandanas, R.A., Leibowitz, D.S., Gharehbaghi, K., Tauchi, T., Burgess, G.S., Miyazawa, K., Jayaram, H.N., and Boswell, H.S. (1993). Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 82, 1838-1847.
31. Manser, E., Leung, T., Salihuddin, H., Zhao, Z., and Lim, L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac 1. Nature 367, 40-46.
32. BCR/ABL. J. Biol. Chem. 269, 5016-5021.
33. McLaughlin, J., Chianese, E., and Witte, O.N. (1987). In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84, 6558-6562.
34. McLaughlin, J., Chianese, E., and Witte, O.N. (1989). Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell. Biol. 9, 1866-1874.
35. McWhirter, J.R., and Wang, J.Y.J. (1991). Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11, 1553-1565.
36. Muller, A.J., Young, J.C., Pendergast, A.-M., Pondel, M., Landau, N.R., Liftman, D.R., and Witte, O.N. (1991). BCR first exon sequences specifically activate Bcr/Abl tyrosine kinase oncogene of Philadelphia chromosome positive human leukemias. Mol. Cell. Biol. 11, 1785-1792.
37. Oda, T., Heaney, C., Hagopian, J.R., Okuda, K., Griffin, J.D., and Druker, B.J. (1994). Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925-22928.
38. Pawson, T. (1995). Protein modules and signaling networks. Nature 373, 573-580.
39. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396.
40. Pendergast, A.M., Muller, A.J., Havlik, M.H., Clark, R., McCormick, F., and Witte, O.N. (1991). Evidence for regulation of the ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA 88, 5927-5931.
41. Pendergast, A.M., Gishizky, M.L., Havlik, M.H., and Witte, O.N. (1993a). SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor-independence. Mol. Cell. Biol. 13, 1728-1736.
42. Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C.H., Dai, Z., Li, N., Batzer, A., Rabun, K.M., Der, C.J., Schlessinger, J., et al. (1993b). BCR-ABL-induced oncogenesisis mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175-185.
43. Piwnica-Worms, H., Saunders, K.B., Roberts, T.M., Smith, A.E., and Cheng, S.H. (1987). Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell 49, 75-82.
44. Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P.G., Arlinghaus, R., and Pawson, T. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J. 13, 764-773.
45. Ren, R., Mayer, B.J., Cicchetti, P., and Baltimore, D. (1993). Identification of a ten-amino acid proline-rich SH3 binding site. Science 259, 1157-1161.
46. Rennick, D., Yang, G., Gemmell, L., and Lee, F. (1987). Control of hemopoiesis by a bone marrow stromal cell clone: lipopolysaccharide- and interleukin-1-inducible production of colony-stimulating factors. Blood 69, 682-691.
47. Rickles, R.J., Botfield, M.C., Weng, Z., Taylor, J.A., Green, O.M., Brugge, J.S., and Zoller, M.J. (1994). Identification of Src,Fyn,Lyn, PI3K and Abl SH3 domain ligands using phage display libraries. EMBO J. 13, 5598-5604.
48. Rosenberg, N., and Witte, O.N. (1988). The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 39, 39-81.
49. Roussel, M.F., Cleveland, J.L., Shurtleff, S.A., and Sherr, C.J. (1991). Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signaling. Nature 353, 361-363.
50. Roussel, M.F., Theodoras, A.M., and Sherr, C.J. (1995). Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. USA 92, 6837-6841.
51. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994). A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 13, 3748-3756.
52. Sawyers, C.L., McLaughlin, J., and Witte, O.N. (1995). Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181, 307-313.
53. Scott, M.L., Van Etten, R.A., Daley, G.Q., and Baltimore, D. (1991). v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc. Natl. Acad. Sci. USA 88, 6506-6510.
54. Soekarman, D., van Denderen, J., Hoefsloot, L., Moret, M., Meeuwsen, T., van Baal, J., Hagemeijer, A., and Grosveld, G. (1990). A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 4, 397-403.
55. Tauchi, T., Boswell, H.S., Leibowitz, D., and Broxmeyer, H.E. (1994). Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J. Exp. Med. 179, 167-175.
56. ten Hoeve, J., Kaartinen, V., Fioretos, T., Haataja, L., Voncken, J.W., Heisterkamp, N., and Groffen, J. (1994). Cellular interactions of CRKL and SH2-SH3 adaptor protein. Cancer Res. 54, 2563-2567.
57. Timmons, M.S., and Witte, O.N. (1989). Structural characterization of the BCR gene product. Oncogene 4, 559-567.
58. Valius, M., and Kazlauskas, A. (1993). Phospholipase C-gamma1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 73, 321-334.
59. Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M. (1993). Complex formation between RAS and RAF and other protein kinases. Proc. Natl. Acad. Sci. USA 90, 6213-6217.
60. Van Etten, R.A., Jackson, P., and Baltimore, D. (1989). The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58, 669-678.
61. Vojtek, A.B., Hollenberg, S.M., and Cooper, J.A. (1993). Mammalian ras interacts directly with the serine/threonine raf. Cell 74, 205-214.
62. Wen, S.T., Jackson, P.K., and Van Etten, R.A. (1996). The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 15, 1583-1595.
63. Yamanashi, Y., and Baltimore, D. (1997). Identification of the Abl-and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 88, 205-211.